HR+/HER2- Metastatic Breast Cancer: key endpoint results by drug
The key endpoints of HR+/HER2- Metastatic Breast Cancer trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the HR+/HER2- Metastatic Breast Cancer page.
PFS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 16.4 | 9.3 | +7.1 | n 446 | NCT02107703 Phase 3, primary |
| Alpelisib (BYL719) | 11 | 5.7 | +5.3 | n 169 | NCT02437318 Phase 3, primary |
| Atezolizumab | 8.2 | 6.8 | +1.4 | n 133 | NCT02924883 Phase 2, primary |
| Bevacizumab | 8.7 | 8 | +0.7 | n 248 | NCT00333775 Phase 3, primary |
| Capecitabine | 5.5 | 5.4 | ±0 | n 266 | NCT01234337 Phase 3, primary |
| Capivasertib | 7.2 | 3.6 | +3.6 | n 355 | NCT04305496 Phase 3, primary |
| Chidamide | 7.4a | 3.8 | +3.6 | — | NCT02482753 Phase 3, primary |
| Culmerciclib | 16.6a | 7.5 | +9.1 | — | NCT05375461 Phase 3, primary |
| Datopotamab Deruxtecan | 6.9 | 4.9 (Investigator's Choice of Chemotherapy (ICC)) | — | n 365 | NCT05104866 Phase 3, primary |
| Docetaxel | 9.5 | 8.2 | +1.3 | n 759 | NCT00703326 Phase 3, primary |
| Elacestrant | 3.8 | 1.9 (Standard of Care (SoC)) | — | n 115 | NCT03778931 Phase 3, primary |
| Eribulin mesylate | 4.1 | 4.2 (Capecitabine) | — | 1.4 mg/m^2 · n 554 | NCT00337103 Phase 3, primary |
| Everolimus | 6.9 | 2.8 | +4.1 | n 485 | NCT00863655 Phase 3, primary |
| Exemestane | 7.3 | 10 (Capecitabine) | — | n 153 | NCT02028507 Phase 3, primary |
| Fulvestrant | 4.7 | 3.8 | +0.9 | n 146 | NCT00390455 Phase 3, primary |
| Gemcitabine | 8.9 | 9.0 (Gemcitabine Plus Docetaxel) | — | n 236 | NCT00191152 Phase 3, secondary |
| Imlunestrant | 5.5 | 5.5 (Investigator's Choice of Endocrine Therapy) | — | n 331 | NCT04975308 Phase 3, primary |
| Inavolisib | 15 | 7.3 | +7.7 | n 161 | NCT04191499 Phase 2/3, primary |
| metformin | 5.4 | 6.3 | −0.9 | n 22 | NCT01310231 Phase 2, primary |
| Nab-paclitaxel | 9.3 | 11.0 (Paclitaxel) | — | n 267 | NCT00785291 Phase 3, primary |
| Neratinib | 12.9 | 12.9 (Trastuzumab + Paclitaxel) | — | n 242 | NCT00915018 Phase 2, primary |
| Olaparib | 7 | 4.2 (Chemotherapy) | — | 300 mg bd · n 205 | NCT02000622 Phase 3, primary |
| Palbociclib | 24.8 | 14.5 | +10.3 | n 444 | NCT01740427 Phase 3, primary |
| Pembrolizumab | 2.1 | 2.6 (Carboplatin) | — | wk 18 · n 51 | NCT03095352 Phase 2, primary |
| Pertuzumab | 14.1 | 13.7 (Trastuzumab + Taxane) | — | n 367 | NCT01120184 Phase 3, primary |
| Ribociclib | 20.5 | 12.8 | +7.7 | n 484 | NCT02422615 Phase 3, primary |
| Sacituzumab Govitecan | 5.5 | 4 (Treatment of Physician's Choice) | — | n 272 | NCT03901339 Phase 3, primary |
| Talazoparib | 8.6 | 5.6 (Physician's Choice Treatment) | — | n 287 | NCT01945775 Phase 3, primary |
| Trastuzumab Emtansine | 14.1 | 13.7 (Trastuzumab + Taxane) | — | n 367 | NCT01120184 Phase 3, primary |
| Vepdegestrant | 3.7 | 3.6 (Fulvestrant) | — | n 313 | NCT05654623 Phase 3, primary |
| Alisertib | 5.6b | — | — | n 46 | NCT02860000 Phase 2, secondary |
| Apatinib | 4.9b | — | — | n 26 | NCT02878057 Phase 2, primary |
| Durvalumab | 2.5b | — | — | 1 mg/kg durvalumab + 3 mg/kg tremelimumab · n 10 | NCT01975831 Phase 1, secondary |
| Enfortumab Vedotin | 5.4b | — | — | n 45 | NCT04225117 Phase 2, secondary |
| Gefitinib | 26.5b | — | — | n 14 | NCT00357734 Phase 3, secondary |
| Goserelin | 21.8b | — | — | n 307 | NCT03096847 Phase 3, secondary |
| Patritumab Deruxtecan | 7.2b | — | — | n 60 | NCT04699630 Phase 2, secondary |
Drugs checked with no result here: 51 not reported, 36 trial running.
OS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 45.8 | 37.3 | +8.5 | n 446 | NCT02107703 Phase 3, secondary |
| Alpelisib (BYL719) | 39.3 | 31.4 | +7.9 | n 169 | NCT02437318 Phase 3, secondary |
| Atezolizumab | 26.5 | 26.0 (Fulvestrant) | — | n 30 | NCT03280563 Phase 1/2, secondary |
| Bevacizumab | 28.8 | 25.8 | +3 | n 239 | NCT01663727 Phase 3, secondary |
| Capecitabine | 16.4 | 15.6 (Capecitabine) | — | n 609 | NCT00082433 Phase 3, primary |
| Capivasertib | 32.8 | — | — | n 54 | NCT01625286 Phase 1/2, secondary |
| Datopotamab Deruxtecan | 18.6 | 18.3 (Investigator's Choice of Chemotherapy (ICC)) | — | n 365 | NCT05104866 Phase 3, primary |
| Docetaxel | 30.3 | 28.7 | +1.6 | n 759 | NCT00703326 Phase 3, secondary |
| Eribulin mesylate | 15.9 | 14.5 (Capecitabine) | — | 1.4 mg/m^2 · n 554 | NCT00337103 Phase 3, primary |
| Everolimus | 31.0 | 26.6 | +4.4 | n 485 | NCT00863655 Phase 3, secondary |
| Exemestane | 33.7 | 32 (Capecitabine) | — | n 206 | NCT02028507 Phase 3, secondary |
| Fulvestrant | 29.9 | 26.4 | +3.5 | n 146 | NCT00390455 Phase 3, secondary |
| Gemcitabine | 23.3 | 23.0 (Gemcitabine Plus Docetaxel) | — | n 236 | NCT00191152 Phase 3, secondary |
| Nab-paclitaxel | 23.5 | 26.6 (Paclitaxel) | — | n 267 | NCT00785291 Phase 3, secondary |
| Neratinib | 19.7 | 23.6 (Lapatinib+Capecitabine) | — | n 117 | NCT00777101 Phase 2, secondary |
| Olaparib | 19.3 | 19.6 (Chemotherapy) | — | 300 mg bd · n 205 | NCT02000622 Phase 3, secondary |
| Palbociclib | 53.9 | 51.2 | +2.7 | n 444 | NCT01740427 Phase 3, secondary |
| Pembrolizumab | 13.4 | 12.5 (Eribulin Mesylate) | — | n 44 | NCT03051659 Phase 2, secondary |
| Pertuzumab | 53.7 | 50.9 (Trastuzumab + Taxane) | — | n 367 | NCT01120184 Phase 3, secondary |
| Ribociclib | 63.9 | 51.4 | +12.5 | n 334 | NCT01958021 Phase 3, secondary |
| Sacituzumab Govitecan | 14.5 | 11.2 (Treatment of Physician's Choice) | — | n 272 | NCT03901339 Phase 3, secondary |
| Talazoparib | 19.3 | 19.5 (Physician's Choice Treatment) | — | n 287 | NCT01945775 Phase 3, secondary |
| Trastuzumab Emtansine | 53.7 | 50.9 (Trastuzumab + Taxane) | — | n 367 | NCT01120184 Phase 3, secondary |
| Zoledronic acid | 26.9 | 32.1 (Zoledronic Acid) | — | n 124 | NCT00365105 Phase 3, secondary |
| Apatinib | 18b | — | — | n 26 | NCT02878057 Phase 2, primary |
| Durvalumab | 19.4b | — | — | 1 mg/kg durvalumab + 3 mg/kg tremelimumab · n 10 | NCT01975831 Phase 1, secondary |
| Gefitinib | 23.5b | — | — | n 14 | NCT00357734 Phase 3, secondary |
| Goserelin | 27.3b | — | — | n 119 | NCT03056755 Phase 2, secondary |
| Methotrexate | 8.2b | — | — | n 3 | NCT00992602 Phase 2, secondary |
Drugs checked with no result here: 51 not reported, 42 trial running, 2 not posted.
ORR
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 35.2% | 16.1% | +19.1 | n 446 | NCT02107703 Phase 3, secondary |
| Alpelisib (BYL719) | 26.6% | 13.4% | +13.2 | n 169 | NCT02437318 Phase 3, secondary |
| Atezolizumab | 10% | 10% (Fulvestrant) | — | n 30 | NCT03280563 Phase 1/2, primary |
| Axitinib | 41.1% | 23.6% (Docetaxel + Placebo) | — | n 112 | NCT00076024 Phase 1/2, secondary |
| Bevacizumab | 54% | 33.2% | +20.8 | n 202 | NCT01663727 Phase 3, secondary |
| Capecitabine | 22.9% | 17.9% (Capecitabine) | — | n 384 | NCT01095003 Phase 3, secondary |
| Docetaxel | 44.7% | 37.9% | +6.8 | n 759 | NCT00703326 Phase 3, secondary |
| Eribulin mesylate | 11% | 11.5% (Capecitabine) | — | 1.4 mg/m^2 · n 554 | NCT00337103 Phase 3, secondary |
| Everolimus | 9.5% | 0.4% | +9.1 | n 485 | NCT00863655 Phase 3, secondary |
| Fulvestrant | 20% | 9% | +11 | n 101 | NCT00390455 Phase 3, secondary |
| Gemcitabine | 19.8% | 12.7% | +7.1 | n 81 | NCT00493636 Phase 2, secondary |
| Imlunestrant | 10.3% | 6.4% (Investigator's Choice of Endocrine Therapy) | — | n 331 | NCT04975308 Phase 3, secondary |
| Nab-paclitaxel | 34.1% | 38.2% (Paclitaxel) | — | n 267 | NCT00785291 Phase 3, secondary |
| Palbociclib | 46.4% | 38.3% | +8.1 | n 444 | NCT01740427 Phase 3, secondary |
| Pembrolizumab | 8% | 12.5% (Carboplatin) | — | wk 18 · n 51 | NCT03095352 Phase 2, secondary |
| Pertuzumab | 88.6% | 78.2% | +10.4 | wk 13 · n 219 | NCT02586025 Phase 3, secondary |
| Ribociclib | 32.4% | 21.5% | +10.9 | n 484 | NCT02422615 Phase 3, secondary |
| Talazoparib | 62.6% | 27.2% (Physician's Choice Treatment) | — | n 219 | NCT01945775 Phase 3, secondary |
| Trastuzumab Emtansine | 59.7% | 67.9% (Trastuzumab + Taxane) | — | n 303 | NCT01120184 Phase 3, secondary |
| Vepdegestrant | 10.9% | 3.6% (Fulvestrant) | — | n 221 | NCT05654623 Phase 3, secondary |
| Alisertib | 19.6%b | — | — | n 46 | NCT02860000 Phase 2, primary |
| Enfortumab Vedotin | 39%b | — | — | n 41 | NCT04225117 Phase 2, primary |
| Exemestane | 14.3%b | — | — | wk 48 · n 49 | NCT01743560 Phase 4, primary |
| Goserelin | 29.3%b | — | — | n 3246 | NCT02941926 Phase 3, secondary |
| Neratinib | 35.9%b | — | — | 240 mg + 25 mg/m² · n 64 | NCT00706030 Phase 1/2, primary |
| Olaparib | 49.6%b | — | — | n 252 | NCT03286842 Phase 3, secondary |
| Patritumab Deruxtecan | 35%b | — | — | n 60 | NCT04699630 Phase 2, primary |
| Pazopanib | 0%b | — | — | wk 156 · n 8 | NCT01498458 Phase 1, secondary |
Drugs checked with no result here: 51 not reported, 43 trial running, 2 not posted.
Clinical benefit rate
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 72.2% | 56.1% | +16.1 | n 446 | NCT02107703 Phase 3, secondary |
| Alpelisib (BYL719) | 61.5% | 44.8% | +16.7 | n 169 | NCT02437318 Phase 3, secondary |
| Atezolizumab | 26.7% | 15% (Fulvestrant) | — | n 30 | NCT03280563 Phase 1/2, secondary |
| Capecitabine | 59% | 53% (Capecitabine) | — | 10 mg + 25 mg · n 104 | NCT01783444 Phase 2, secondary |
| Docetaxel | 60.4% | 62% (Trastuzumab) | — | n 326 | NCT00667251 Phase 3, secondary |
| Everolimus | 33.4% | 18% | +15.4 | n 485 | NCT00863655 Phase 3, secondary |
| Fulvestrant | 78.3% | 74.1% (Anastrozole) | — | 500 mg · n 230 | NCT01602380 Phase 3, secondary |
| Imlunestrant | 46.8% | 45.5% (Investigator's Choice of Endocrine Therapy) | — | n 331 | NCT04975308 Phase 3, secondary |
| Neratinib | 88.4% | 85.2% (Trastuzumab + Paclitaxel) | — | n 242 | NCT00915018 Phase 2, secondary |
| Palbociclib | 85.8% | 71.2% | +14.6 | n 444 | NCT01740427 Phase 3, secondary |
| Ribociclib | 70.2% | 62.8% | +7.4 | n 484 | NCT02422615 Phase 3, secondary |
| Vepdegestrant | 34.3% | 28.7% (Fulvestrant) | — | n 274 | NCT05654623 Phase 3, secondary |
| Alisertib | 41.3%b | — | — | wk 24 · n 46 | NCT02860000 Phase 2, secondary |
| Eribulin mesylate | 57.1%b | — | — | 1.4 mg/m^2 · n 42 | NCT01323530 Phase 1/2, secondary |
| Exemestane | 48.2%b | — | — | n 199 | NCT03176238 Phase 3, secondary |
| Goserelin | 70.7%b | — | — | n 3246 | NCT02941926 Phase 3, secondary |
| Nab-paclitaxel | 86.2%b | — | — | n 1198 | NCT01572038 Phase 3, secondary |
| Patritumab Deruxtecan | 48.3%b | — | — | n 60 | NCT04699630 Phase 2, secondary |
| Pazopanib | 25%b | — | — | wk 156 · n 8 | NCT01498458 Phase 1, secondary |
| Pembrolizumab | 50%b | — | — | n 10 | NCT02648477 Phase 2, secondary |
| Pertuzumab | 86.2%b | — | — | n 1198 | NCT01572038 Phase 3, secondary |
Drugs checked with no result here: 55 not reported, 44 trial running, 4 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 124 approved or late-stage drugs with a featured trial in HR+/HER2- Metastatic Breast Cancer were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.